The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
 
Lisa Zimmer
Stock and Other Ownership Interests - Bayer
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
 
Florentia Dimitriou
Honoraria - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Sun Pharma
 
Piyush Grover
No Relationships to Disclose
 
Jessica Cecile Hassel
Honoraria - Amgen; BMS GmbH & Co. KG; Bristol Myers Squibb Foundation; GlaxoSmithKline; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); GlaxoSmithKline; Immunocore (Inst); MSD; Novartis (Inst); Onkowissen; Philogen (Inst); Pierre Fabre; Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); Idera (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - 4SC; BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Michael Erdmann
Honoraria - Immunocore
Consulting or Advisory Role - Immunocore
Travel, Accommodations, Expenses - Novartis
 
Andrea Forschner
Honoraria - BMS GmbH & Co. KG; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - BMS GmbH & Co. KG; Immunocore; MSD; Novartis; Pierre Fabre
Research Funding - Bristol-Myers Squibb Stiftung Immunonkologie (Inst)
Travel, Accommodations, Expenses - Novartis; Pierre Fabre
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Mallinckrodt; Merck; Mosaic ImmunoEngineering; Novartis; Oncosec; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Elisabeth Livingstone
Honoraria - Bristol-Myers Squibb; Novartis; Pierre Fabre; Recordati; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Pierre Fabre; Sun Pharma
 
Alexander Roesch
Honoraria - BMS GmbH & Co. KG; Novartis
Research Funding - Novartis (Inst)
 
Selma Ugurel
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Pierre Fabre
 
Carsten Schulz
No Relationships to Disclose
 
Carola Berking
Honoraria - Almirall Hermal GmbH; Bristol-Myers Squibb; LEO Pharma; MSD; Novartis; Sanofi/Aventis
Consulting or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; Immunocore; InflaRx; MSD; Novartis; Pierre Fabre; Sanofi/Aventis; Sanofi/Regeneron
Research Funding - Almirall Hermal GmbH (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); InflaRx (Inst); IO Biotech (Inst); Kartos Therapeutics (Inst); Pfizer (Inst)
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Lea Jessica Albrecht
Honoraria - BMS; Novartis; Sun Pharma
Travel, Accommodations, Expenses - Sanofi; Sun Pharma; Takeda